<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="114277">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01871467</url>
  </required_header>
  <id_info>
    <org_study_id>KW-5001-1</org_study_id>
    <nct_id>NCT01871467</nct_id>
  </id_info>
  <brief_title>Sargramostim for Myeloid Dendritic Cell Deficiency</brief_title>
  <official_title>Sargramostim for Myeloid Dendritic Cell Deficiency - Phase I</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Previous studies have demonstrated a deficiency of blood dendritic cells in patients with
      kidney disease that is associated with the development of viral infections after kidney
      transplantation. We plan to test the ability of sargramostim to increase blood dendritic
      cell levels in patients with kidney disease in the hopes of developing new therapies to
      prevent viral infections after kidney transplantation.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2013</start_date>
  <primary_completion_date type="Anticipated">April 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label</study_design>
  <primary_outcome>
    <measure>Target blood myeloid dendritic cell level of &gt; 2.0 x 10&lt;4&gt;/mL</measure>
    <time_frame>2-4 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Dendritic Cell Deficiency</condition>
  <arm_group>
    <arm_group_label>Sargramostim administration</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive sargramostim.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sargramostim</intervention_name>
    <arm_group_label>Sargramostim administration</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt;18 years &lt; 80 years with diagnosis of end stage renal disease and currently
             undergoing outpatient hemodialysis (HD) at one of the Johns Hopkins
             University-affiliated HD units

        Exclusion Criteria:

          -  Age&lt;18or&gt;80years

          -  History of non-adherence to prescribed HD treatment

          -  Active drug or heavy alcohol use (defined as &gt; 4 drinks/day)

          -  Pregnancy or breast feeding

          -  Active infection (bacterial or viral) or clinically significant infections within the
             past three months (e.g. those requiring hospitalization, or as judged by the PI)

          -  Active malignancy (with the exception of excised non-metastatic basal cell carcinoma
             or squamous cell carcinoma of the skin, or adequately treated pre- invasive cervical
             cancer in situ)

          -  Unstable cardiovascular status (angina, arrhythmias, congestive heart failure etc...)

          -  History of liver disease (as defined by a diagnosis of uncompensated cirrhosis) â€¢
             History of lung disease (including moderate-severe chronic obstructive pulmonary
             disease, interstitial lung disease, or asthma)

          -  Known hypersensitivity to yeast-derived products

          -  Hemoglobin &lt; 10 g/dL and hematocrit &lt; 30%.

          -  Abnormal white blood cell (WBC) count at baseline (&lt; 3 or &gt; 12 x 10 cells/mm )

          -  Treatment with WBC growth factors (G-CSF or GM-CSF) or immunosuppressive medications
             (tacrolimus, cyclosporine, mycophenolate, azathioprine, corticosteroids,
             chlorambucil, cyclophosphamide) within 4 weeks of study (erythropoiesis-stimulating
             agents will be allowed)

          -  Treatment with lithium within 4 weeks of study
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karl L Womer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Karl L Womer, MD</last_name>
    <phone>410-502-3707</phone>
    <email>kwomer1@jhmi.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karl L Womer, MD</last_name>
      <phone>410-502-3707</phone>
      <email>kwomer1@jhmi.edu</email>
    </contact>
    <investigator>
      <last_name>Karl L Womer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <lastchanged_date>June 5, 2013</lastchanged_date>
  <firstreceived_date>June 4, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Johns Hopkins University</investigator_affiliation>
    <investigator_full_name>Karl L. Womer, MD</investigator_full_name>
    <investigator_title>Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
